SLGL - Earnings announcements

Patidegib, an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025Conference call to be held this morning at 8:30 a.m. U.S. ET NESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative dermatology products that were launched in the U.S. by partner Galderma during 2022, announced today the acquisition of topically-applied patidegib, a hedgehog sig

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET. About Sol-Gel Technologies  Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO® under investigation for